The basic goal of this proposal is to combine the power of combinatorial chemistry with the modern knowledge of cancer biology and genetics in an effort to identify novel anticancer compounds. The program project consists of one chemistry and two biology projects and two cores. The first project (Boger) proposes the production and testing of libraries targeted to protein-protein and protein-DNA interactions. The libraries produced in the past funding period will be increased to 10[6] compounds and lead optimization will continue. Project two (Cheresh) deals with the isolation of angiogenesis inhibitors. It will develop inhibitors of matrix metalloproteinase 2, refine the nanoparticle genes delivery technology of the past funding period and test inhibitors of integrin alpha3beta1. Project 3 (Vogt) proposes the isolation of small molecule regulators of the Myc network and of beta-catenin-LEF interaction. It will also continue the identification and optimization of lead anticancer compounds through cellular and in vitro assays. The cores are for animal studies and instruments. The research projects are connected and interdependent. The interactions are mutual; the reiterative process of library and compound optimization rests on the interchange of chemical materials and of biological information. The collaborating groups of this Program Project have become an integrated unit that incorporates a wide range of expertise and interests and applies them to the common goal, new anticancer compounds.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
5P01CA078045-09
Application #
7183585
Study Section
Subcommittee G - Education (NCI)
Program Officer
Song, Min-Kyung H
Project Start
1998-05-07
Project End
2009-02-28
Budget Start
2007-03-01
Budget End
2008-02-29
Support Year
9
Fiscal Year
2007
Total Cost
$1,316,611
Indirect Cost
Name
Scripps Research Institute
Department
Type
DUNS #
781613492
City
La Jolla
State
CA
Country
United States
Zip Code
92037
Gochin, Miriam; Whitby, Landon R; Phillips, Aaron H et al. (2013) NMR-assisted computational studies of peptidomimetic inhibitors bound in the hydrophobic pocket of HIV-1 glycoprotein 41. J Comput Aided Mol Des 27:569-82
Whitby, Landon R; Boger, Dale L (2012) Comprehensive peptidomimetic libraries targeting protein-protein interactions. Acc Chem Res 45:1698-709
Hart, Jonathan R; Liao, Lujian; Yates 3rd, John R et al. (2011) Essential role of Stat3 in PI3K-induced oncogenic transformation. Proc Natl Acad Sci U S A 108:13247-52
Whitby, Landon R; Ando, Yoshio; Setola, Vincent et al. (2011) Design, synthesis, and validation of a ýý-turn mimetic library targeting protein-protein and peptide-receptor interactions. J Am Chem Soc 133:10184-94
Shields, D J; Murphy, E A; Desgrosellier, J S et al. (2011) Oncogenic Ras/Src cooperativity in pancreatic neoplasia. Oncogene 30:2123-34
Murphy, Eric A; Majeti, Bharat K; Mukthavaram, Rajesh et al. (2011) Targeted nanogels: a versatile platform for drug delivery to tumors. Mol Cancer Ther 10:972-82
Hart, Jonathan Ross; Liao, Lujian; Ueno, Lynn et al. (2011) Protein expression profiles of C3H 10T1/2 murine fibroblasts and of isogenic cells transformed by the H1047R mutant of phosphoinositide 3-kinase (PI3K). Cell Cycle 10:971-6
Kolesnichenko, Marina; Vogt, Peter K (2011) Understanding PLZF: two transcriptional targets, REDD1 and smooth muscle ?-actin, define new questions in growth control, senescence, self-renewal and tumor suppression. Cell Cycle 10:771-5
Thomas, Celestine J; Casquilho-Gray, Hedi E; York, Joanne et al. (2011) A specific interaction of small molecule entry inhibitors with the envelope glycoprotein complex of the Junín hemorrhagic fever arenavirus. J Biol Chem 286:6192-200
Sun, Minghao; Hart, Jonathan R; Hillmann, Petra et al. (2011) Addition of N-terminal peptide sequences activates the oncogenic and signaling potentials of the catalytic subunit p110? of phosphoinositide-3-kinase. Cell Cycle 10:3731-9

Showing the most recent 10 out of 85 publications